NCT02443428View on ClinicalTrials.gov

Eribulin Use for the Treatment of Advanced Breast Cancer: A Prospective Observational Registry

CompletedOBSERVATIONAL
Enrollment

77

Participants

Timeline

Start Date

August 31, 2013

Primary Completion Date

October 31, 2015

Study Completion Date

October 31, 2015

Conditions
Breast Cancer
Trial Locations (12)

Unknown

Aarhus

Copenhagen

Dublin

Bath

Cottingham

Derby

London

Maidstone

Manchester

Norwich

Oxford

Plymouth

All Listed Sponsors
lead

Eisai Limited

INDUSTRY

NCT02443428 - Eribulin Use for the Treatment of Advanced Breast Cancer: A Prospective Observational Registry | Biotech Hunter | Biotech Hunter